Cardiol Therapeutics Inc.

NASDAQ:CRDL

Drug Manufacturers - Specialty & Generic

Healthcare
$0.95 -0.47%

-$0.01 today

Market cap
$114.64M
Beta
0.80
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $0.88High $1.71

Volume 0.31M

Average 0.68M

CRDL Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Cardiol Therapeutics Inc.NASDAQ: CRDL

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 19.1% from a year ago

Cash & equivalents stood at CA$27.74M at the end of Q1 FY2026, up 19.1% from a year earlier and up 29.5% from the prior quarter. Over 3 fiscal years it compounded at -21.2% a year.

Context

  • Cash & equivalents amounted to 88.1% of total assets at the end of Q1 FY2026, down 3.4 pp from a year earlier.
  • Cash & equivalents increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +19.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$27.74M+29.5% QoQ
Last fiscal yearDec 2025
CA$21.42M-30.0% YoY
Year agoMar 2025
CA$23.29M+19.1% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.1%——
1 year-30.0%——
3-year CAGR-21.2%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

CAD · from the balance sheet

Latest · FY2025
21.42M CAD
Year-over-year change
-30.0%
4-year CAGR
-28.9%

Cash & Equivalents vs competitors

How CRDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +19.1% is the 4th highest of 10, against a peer median of -3.7%.
  • Cash & equivalents amounts to 88.1% of total assets for CRDL, versus a peer median of 31.4%.
CRDL Competitors
Cash & Equivalents for CRDL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMAImageneBio IncMar 2026$76.05M USD+106.9%-16.4%55.6%
INCRInterCure Ltd.Dec 2025₪46.47M ILS-40.7%-41.5%6.7%
HYPRHyperfine, Inc.Mar 2026$40.78M USD+23.2%-33.3%67.6%
CNTBConnect Biopharma Holdings LimitedDec 2025$38.35M USD-51.0%-21.4%68.4%
KLRSKalaris Therapeutics IncMar 2026$34.43M USD-65.9%+217.7%31.4%
ASRTAssertio Holdings, Inc.Mar 2026$33.71M USD-3.7%-46.0%16.0%
CRDLCardiol Therapeutics Inc.Mar 2026CA$27.74M CAD+19.1%-21.2%88.1%
VANIVivani Medical, Inc.Mar 2026$19.75M USD+51.8%-28.9%46.6%
IFRXInflaRx N.V.Mar 2026€15.01M EUR-68.3%-0.5%30.7%
MBOTMicrobot Medical Inc.Mar 2026$3.66M USD+13.7%+15.8%4.7%
Peer median (excluding CRDL) —-3.7%-21.4%31.4%

Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents83.9M43.83M34.93M30.58M21.42M
Short-term Investments045.65K000
Net Receivables65.74K354.24K279.87K361.62K226.2K
Inventory00000
Other Current Assets341.39K0000
Total Current Assets87.14M45.32M36.15M31.67M23.5M
Property, Plant & Equipment (Net)356.49K218.17K337.06K195.59K118.09K
Goodwill00000
Intangible Assets379.25K217.48K210.36K00
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets735.74K435.64K547.42K195.59K118.09K
Total Assets87.88M45.76M36.7M31.86M23.62M
Account Payables4.14M6.16M7.62M6.98M0
Short-term Debt037.21K000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities6.66M1.04M238.18K05.62M
Total Current Liabilities11.57M7.23M8.3M7.01M5.66M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities(0)0000
Total Non-current Liabilities72.87K16.54K158.53K125.52K87.18K
Total Liabilities11.64M7.25M8.45M7.14M5.74M
Common Stock142.92M108.84M148.52M179.34M201.87M
Retained Earnings(83.52M)(84.43M)(142.58M)(179.25M)(213.07M)
Accumulated OCI4.18M2.6M3.52M00
Other Stockholders Equity8290(666)00
Minority Interest00000
Total Equity76.24M38.51M28.25M24.73M17.88M
Total Debt117.58K53.76K174.34K158.53K125.52K
Net Debt(83.78M)(43.77M)(34.76M)(30.42M)(21.29M)

Cardiol Therapeutics Inc.

NASDAQ:CRDL

Intrinsic Alpha fair value

Locked

Current Price

$0.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.